Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Other Accumulated Expenses: 2009-2024

Historic Other Accumulated Expenses for Cumberland Pharmaceuticals (CPIX) over the last 16 years, with Dec 2024 value amounting to $12.3 million.

  • Cumberland Pharmaceuticals' Other Accumulated Expenses fell 20.34% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year decrease of 20.34%. This contributed to the annual value of $12.3 million for FY2024, which is 9.90% down from last year.
  • Per Cumberland Pharmaceuticals' latest filing, its Other Accumulated Expenses stood at $12.3 million for FY2024, which was down 9.90% from $13.6 million recorded in FY2023.
  • Cumberland Pharmaceuticals' 5-year Other Accumulated Expenses high stood at $17.6 million for FY2022, and its period low was $8.7 million during FY2021.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $13.6 million (2023), whereas its average is $14.5 million.
  • As far as peak fluctuations go, Cumberland Pharmaceuticals' Other Accumulated Expenses decreased by 22.98% in 2021, and later spiked by 102.90% in 2022.
  • Over the past 5 years, Cumberland Pharmaceuticals' Other Accumulated Expenses (Yearly) stood at $11.3 million in 2020, then decreased by 22.98% to $8.7 million in 2021, then spiked by 102.90% to $17.6 million in 2022, then dropped by 22.69% to $13.6 million in 2023, then declined by 9.90% to $12.3 million in 2024.